Table 5.
Clinical trials based on TCR-T against cervical cancer.
| Trial N. | Target | Condition | Phase | Patients N. | Start | Status |
|---|---|---|---|---|---|---|
| NCT02280811 | E6 | HLA-A*02:01-positive HPV-16-associated metastatic/recurrent cancer | I, II | 12 | 2014 | Compl. (2016) |
| NCT02153905 | MAGE-A3 | HLA-A 01-positive metastatic/recurrent cancer expressing MAGE-A3 | I, II | 3 | 2014 | Compl. (2018) |
| NCT02111850 | MAGE-A3 | (HLA)-DP0401/0402-positive metastatic/recurrent cancer expressing MAGE-A3-DP4 | I, II | 21 | 2014 | Compl. (2021) |
| NCT02858310 | E7 | HLA-A*02:01-positive HPV-16-associated metastatic/recurrent cancer | I, II | 180 | 2017 | Pending Est. compl.: 2026 |
| NCT03578406 | E6 + PD-1 | Metastatic/recurrent HPV-16-positive cancers | I | 20 | 2018 | Pending |
| NCT05357027 | E6 | HLA-A*02- and HPV16-positive metastatic/recurrent positive cervical cancer | I, II | 18 | 2022 | Pending Est. compl.: 2024 |
| NCT05122221 | E7 | HLA-A*02- and HPV16-positive cancer | I | 12 | 2022 | Pending Est. compl.: 2024 |